TGX-115

TGX-115 is a p110β/p110δ-selective, PI3-K inhibitor. TGX-115 blocks p110β-mediated Akt phosphorylation induced by lysophosphatidic acid (LPA) in L6 myotubes, reduces insulin-stimulated PI (3,4) P2 and PIP3 levels in 3T3-L1 adipocytes. TGX-115 can be used for the study of diabetes mellitus[1][2].

Product Specifications

CAS Number

[351071-62-0]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

PI3K

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/tgx-115.html

Purity

99.25

Solubility

10 mM in DMSO

Smiles

O=C1C=C(N2CCOCC2)NC3=C1C=CC=C3OC4=C(C)C=CC=C4

Molecular Formula

C20H20N2O3

Molecular Weight

336.38

Precautions

H315, H319

References & Citations

[1]Fan QW, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006 May;9 (5) :341-9. |[2]Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125 (4) :733-47.